The KM survival analysis showed that low tumor B7-H3 expression was markedly associated with favorable 5-year DFS (62.8% vs. 45.1%, p<0.001, Fig. 1E) and 5-year OS (66.5% vs. 54.2%, p=0.02, Fig. 1F and Table S2) in stage I-IV patients. Here, CD276 is linked to neoplasm.